#Dividend #Ireland #Medtronic #Galway #fiscal year 2026

Medtronic Approves Cash Dividend for Q4 of Fiscal Year 2026

Medtronic plc, a prominent player in healthcare technology, announced on March 5, 2026, that its board of directors has approved a cash dividend of $0.71 per ordinary share for the fourth quarter of the fiscal year 2026. This announcement reiterates the company’s commitment to returning value to its shareholders, following a similar increase declared in May 2025.

As part of the S&P 500 Dividend Aristocrats index, Medtronic has demonstrated a robust track record by increasing its annual dividend for 48 consecutive years. This long-standing commitment reflects Medtronic's consistent performance and dedication to its investors. The upcoming dividend will be payable on April 17, 2026, to shareholders on record as of the close of business on March 27, 2026. This timeline allows shareholders to plan their investments and demonstrates the company’s steady financial health.

About Medtronic

Founded in Galway, Ireland, Medtronic is recognized globally as a leader in healthcare technology, dedicated to addressing complex health challenges. Their mission focuses on alleviating pain, restoring health, and extending life. With a dynamic team of over 95,000 employees across more than 150 countries, Medtronic’s innovative technologies span various fields. The company’s diverse portfolio includes cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems, among others, making a significant impact in managing over 70 health conditions.

The company leverages its extensive knowledge base, curiosity, and collective commitment to improve healthcare globally. Every second, Medtronic’s technologies help transform the lives of two individuals, showcasing the profound effect of their commitment to patient care and innovation. As a forward-thinking corporation, Medtronic consistently seeks insights-driven solutions that emphasize patient-centric care and improved health outcomes.

Investors and stakeholders should continue to monitor Medtronic's progress as it seeks new areas for growth and innovation while upholding its legacy of reliability and excellence in healthcare technology. The ongoing increase in dividends underscores Medtronic's financial strength and operational success and assures investors of the company’s long-term vision and stability.

In conclusion, the declaration of a cash dividend solidifies Medtronic's status as a dynamic leader in the healthcare landscape, known for its forward-thinking ethos and an unwavering commitment to both patient and shareholder satisfaction.

For more detailed information about Medtronic and their latest updates, you can visit Medtronic's official site or follow them on their corporate LinkedIn channel.

Contact Information

For further inquiries, members of the media can reach out to Justin Paquette in Public Relations at +1-612-271-7935, or Ingrid Goldberg in Investor Relations at +1-763-505-2696.

Shareholders and interested parties are encouraged to keep an eye on Medtronic’s periodic reports and updates, reflecting the company’s performance and strategic initiatives in the coming months.